Substitution of lysine 27 with methionine in histone H3.3 is a recently discovered driver mutation of pediatric high-grade gliomas. Tumor cells carrying this oncohistone show decreased levels of polycomb silencing as a result of physical inhibition of PRC2 methyltransferase activity, but how these chromatin changes lead to tumorigenisis remains unclear. To gain insight into the interplay between PRC2 activity and H3.3K27M incorporation, we introduced this mutation to the C. elegans H3.3 homologue
his-72 and examined its genomic and phenotypic consequences in the context of a whole organism. Worms carrying the H3.3K27M mutation suffer from ectopic replication and cell cycle progression in the proximal germline. Our detailed chromatin analysis provides mechanistic insight into how the H3.3K27M remodels polycomb silencing genome-wide. Our data supports a model where the PRC2 activity is locally both inhibited by H3.3K27M incorporation and stimulated by pre-existing H3K27me3 in a concentration-dependent way. Through unbiased genetic screening, we identified the JNK pathway as a key driver of H3.3K27-induced DNA replication and cell cycle progression. We show that the replicative cell fate is reversible by targeting JNK in both nematodes and human tumor-derived H3.3K27M cells, and thus establish C. elegans as a powerful model for the identification of potential drug targets for treatment of H3.3K27M tumors.